Skip to content

Topic

Biosimilars

Biologic drugs clinically equivalent to an approved reference biologic, typically sold at lower cost, similar in role to generics for small-molecule drugs.

Current stories

investOne report1 publisher

U.S. and Europe now take 52% of Korea's food, beauty and bio exports, up from 19% in 2016

Korean exports of seven food, beauty and bio products reached $15.59 billion in January-August, 4.2 times 2016 against 2.2 times for all exports. On the chamber's figures the U.S. and Europe now take 52% of it, up from 19%.

Reality

Evidence62
Adoption
Not scored
Hype gap+8
Incentives40
Confidence60
investConfirmed2 publishers

Europe lifts Korea's biopharma exports to a record $6.6 billion

South Korea's biopharma exports rose 15.8% to a record $6.6 billion in the first nine months, led by Europe, the drug safety ministry said. With US shipments down 23.7%, Seoul Economic Daily reported, the record rests on European contract manufacturing and biosimilar demand.

Perspective Coverage

3 publishers
Builder
Builder 13%
Operator
Operator 37%
Investor
Investor 50%

Reality

Evidence72
Adoption60
Hype gap+8
Incentives35
Confidence70
investConfirmed4 publishers

Thyme Care raises Series E led by Morgan Health at 16 times revenue, with Humana and CVS Health Ventures joining

Morgan Health led a Series E of more than $125m that values Thyme Care above $2bn, roughly double its mark from under a year ago. The payers on the cap table are underwriting a savings number the company validated itself.

Publishers:cnbc.com medcitynews.com prnewswire.com techfundingnews.com

Perspective Coverage

4 publishers
Builder
Builder 12%
Operator
Operator 39%
Investor
Investor 49%

Reality

Evidence55
Adoption45
Hype gap+30
Incentives70
Confidence60